Healthcare
Healthcare Investment Banking Group
Finding financial solutions across every sector of the healthcare ecosystem.
A full-service healthcare investment banking practice offering a best-in-class combination of deep sector knowledge, strong industry relationships, and broad product expertise.
Stifel’s Global Healthcare Investment Banking Group is comprised of 47 professionals covering all segments of the healthcare industry. The team, located in New York, San Francisco, London, Toronto, and Montreal, has substantial experience in assisting companies with all types of financing and M&A assignments. The Global Healthcare Group is dedicated to building long-term relationships with its clients through senior level attention. Since the formation of the Global Healthcare Group in Q4 2010, the team have helped raise over $79.1 billion for over 225 healthcare companies in over 440 transactions. Over the same period, members of the Global Healthcare Group have advised on over 105 announced M&A transactions, including over 30 cross-border assignments.
Our team provides clients with strategic advisory and capital-raising services designed to support growth companies and their investors during all stages of their development. We offer equity and debt capital markets services, including book running leading IPOs, follow-ons, and convertible note issuances. The Global Healthcare Group is supported by M&A advisory with extensive cross-border expertise, access to private capital markets through SPACs and 144A solutions, as well as activism defense and restructuring.
Read Our Latest Thoughts on Investment Banking in the Healthcare Sector
Learn MoreAreas of Expertise
The biopharma sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all stages of development and therapeutic areas. Stifel’s Biopharma team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the biopharma landscape, and our extensive relationships and transaction experience.
The healthcare services landscape is constantly shifting, driven by changes in regulations, reimbursement, and advancements in technology. Stifel’s Healthcare Services Team works to stay abreast of these changes and is ideally positioned to serve the needs of our clients in all types of financing and M&A assignments via relationships, recent mandates, and years of thought leadership across a broad range of healthcare sub-sectors including Alternate Site, Behavioral Health, Payor Services, Pharma Services, and Physician Groups.
Technologies are rapidly advancing the automation of workflows across the healthcare ecosystem, the development and efficacy of treatments, and the way in which care is provided in-person and remotely. Stifel’s Healthcare Technology team brings a wealth of M&A and financing experience advising companies delivering software, digital health, data-driven, and technology-enabled solutions to providers, payors, pharmaceutical companies, and patients.
The Medtech sector is advancing at an unprecedented pace, driven by innovation and growth from small to large companies across all Medtech subsectors. Stifel’s Medtech team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our deep understanding of the Medtech landscape, and our extensive relationships and transaction experience.
The life science tools & diagnostics sector is transforming at amazing speeds. Enabled by a broad array of new technologies, our ability to better understand all facets of the human genome has improved exponentially; all the while being done at greater efficiency and dramatically reduced costs. This widening knowledge set is enabling faster and more productive drug discovery, disease diagnosis and AI-enabled prognostic clinical capabilities. Stifel’s Life Science Tools & Diagnostics team is uniquely positioned to serve the needs of our clients in all types of financing and M&A assignments via our broad domain expertise, deep understanding of the competitive landscape, and our extensive relationships and transaction experience.
Notable Transactions

Follow-on Offering
Biopharma
Mar 2025

Initial Public Offering
Medtech
Mar 2025

Follow-on Offering
Biopharma
Feb 2025

Mergers & Acquisitions
Healthcare
Feb 2025

Initial Public Offering
Biopharma
Feb 2025

Follow-on Offering
Biopharma
Jan 2025

Mergers & Acquisitions
HealthTech
Dec 2024

Registered Direct
Biopharma
Dec 2024

Follow-on Offering
Biopharma
Dec 2024

Mergers & Acquisitions
HealthTech
Dec 2024

Follow-on Offering
Biopharma
Dec 2024

Registered Direct & PIPE
Biopharma
Nov 2024

Mergers & Acquisitions
Medtech, Healthcare
Jul 2024

Mergers & Acquisitions
Healthcare, Biopharma
Aug 2024

Mergers & Acquisitions
Healthcare Services
Oct 2024

Mergers & Acquisitions
Biopharma
Oct 2024

Follow-on Offering
Biopharma
Sep 2024

Initial Public Offering
Biopharma
Sep 2024

Initial Public Offering
Biopharma
Sep 2024

PIPE
Biopharma
Sep 2024

Follow-on Offering
Biopharma
Sep 2024

Follow-on Offering
Biopharma
Sep 2024

Confidentially Marketed Follow-on Offering
Biopharma
Aug 2024

Registered Direct
Biopharma
Aug 2024

Follow-on Offering
Biopharma
Aug 2024

Convertible Notes & Senior Secured Term Loan
Medtech
Aug 2024

SPAC Merger
Medtech
Jul 2024

Mergers & Acquisitions
Healthcare
Jul 2024

Mergers & Acquisitions
HealthTech
Jul 2024

Mergers & Acquisitions
Biopharma
Jul 2024

Secured Credit Facility
Healthcare
Jun 2024

Initial Public Offering
Biopharma
Jun 2024

Registered Direct
Biopharma
May 2024

Follow-on Offering
Biopharma
May 2024

Registered Direct
Biopharma
May 2024

Has Sold Assets to
Medtech
Apr 2024

Aggregate Indebtedness
Medtech
Apr 2024

PIPE
Biopharma
Apr 2024

Confidentially Marketed Follow-on Offering
Biopharma
Apr 2024

Mergers & Acquisitions
Biopharma
Apr 2024

Initial Public Offering
Biopharma
Apr 2024

Mergers & Acquisitions
Biopharma
Mar 2024

Follow-on Offering
Healthcare & Special Situations
Mar 2024

Registered Direct
Biopharma
Mar 2024

Registered Direct
Biopharma
Mar 2024

PIPE
Biopharma
Mar 2024

Follow-on Offering
Biopharma
Mar 2024

Follow-on Offering
Biopharma
Mar 2024

Follow-on Offering
Healthcare
Mar 2024

Mergers & Acquisitions
Healthcare Services
Mar 2024

Follow-on Offering
Biopharma
Feb 2024

Mergers & Acquisitions
HealthTech
Feb 2024

Follow-on Offering
Biopharma
Feb 2024

Confidentially Marketed Follow-on Offering
Biopharma
Feb 2024

Follow-on Offering
Biopharma
Jan 2024

Confidentially Marketed Follow-on Offering
Biopharma
Dec 2023

Registered Direct
HealthTech
Dec 2023

PIPE
Biopharma
Dec 2023

Mergers & Acquisitions
Biopharma
Dec 2023

Mergers & Acquisitions
Biopharma
Nov 2023

Confidentially Marketed Follow-on Offering
Biopharma
Nov 2023

In-Licensing
Biopharma
Nov 2023

Mergers & Acquisitions
HealthTech
Nov 2023

Initial Public Offering
Biopharma
Nov 2023

Confidentially Marketed Follow-on Offering
Medtech
Oct 2023

Confidentially Marketed Follow-on Offering
Biopharma
Oct 2023

Mergers & Acquisitions
Medtech
Oct 2023

Mergers & Acquisitions
Biopharma
Oct 2023

Registered Direct
Biopharma
Oct 2023

Mergers & Acquisitions
Healthcare
Sep 2023

Initial Public Offering
Biopharma
Sep 2023

Confidentially marketed Follow-on Offering
Biopharma
Sep 2023

Initial Public Offering
Biopharma
Jul 2023

Follow-on Offering
Biopharma
Jul 2023

Equity Placing
Healthcare
Jul 2023

Chapter 11 Restructuring
Biopharma
Jun 2023

Confidentially Marketed Follow-on Offering
Biopharma
Jun 2023

Follow-on Offering
Biopharma
Jun 2023

Follow-on Offering
Biopharma
Mar 2023

PIPE
Healthcare
Feb 2023

Initial Public Offering
Biopharma
Feb 2023

Confidentially Marketed Follow-on Offering
Medtech
Feb 2023

Follow-on Offering
Biopharma
Jan 2023

Convertible Notes
Medtech
Dec 2022

Confidentially Marketed Follow-on Offering
Biopharma
Dec 2022

Mergers & Acquisitions
Healthcare
Dec 2022

Registered Direct & PIPE
Biopharma
Dec 2022

Mergers & Acquisitions
Maritime Services, Healthcare Services
Dec 2022

Confidentially Marketed Follow-on Offering
Biopharma
Dec 2022

Mergers & Acquisitions
Tools & Diagnostics
Nov 2022

Mergers & Acquisitions
Biopharma
Nov 2022

Convertible Bond & Follow-on Offering
Healthcare Services
Oct 2022

Mergers & Acquisitions
Biopharma
Sep 2018

Strategic Financing Agreement
Biopharma
Feb 2019

Follow-on Offering
Medtech
Oct 2022

Confidentially Marketed Follow-on Offering
Biopharma
Sep 2022

Confidentially Marketed Follow-on Offering
Biopharma
Sep 2022

Mergers & Acquisitions
Healthcare Services
Aug 2022

Confidentially Marketed Follow-on Offering
Biopharma
Aug 2022

Follow-on Offering
Biopharma
Aug 2022

Confidentially Marketed Follow-on Offering
Medtech
Aug 2022

Exchange of Convertible Notes
Medtech
Jul 2022

Senior Secured Term Loan
Medtech
Jul 2022

Mergers & Acquisitions
Medtech
Jul 2022

Confidentially Marketed Follow-on Offering
HealthTech
Jun 2022

Follow-on Offering
Biopharma
May 2022

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2020

Follow-on Offering
HealthTech
May 2022

Initial Public Offering
Biopharma
May 2022

Mergers & Acquisitions
Healthcare Services
May 2022

Mergers & Acquisitions
Medtech
Apr 2020

Private Placement
Biopharma
Nov 2021

Registered Direct
HealthTech
Mar 2022

Initial Public Offering
Biopharma
Apr 2022

Confidentially Marketed Follow-on Offering
Biopharma
Apr 2022

Follow-on Offering
Healthcare
Apr 2022

Convertible Bond and Equity Placing
Medtech
Mar 2022

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2022

Follow-on Offering
Biopharma
Mar 2022

Senior Notes
HealthTech
Feb 2022

Confidentially Marketed Follow-on Offering
Biopharma
Jan 2022

Initial Public Offering
Biopharma
Jan 2022

Mergers & Acquisitions
Healthcare Services
Dec 2021

Follow-on Offering
Biopharma
Dec 2021

SPAC IPO
Biopharma
Nov 2021

Convertible Notes
HealthTech
Nov 2021

Confidentially Marketed Follow-on Offering
Medtech
Nov 2021

Follow-on Offering
Tools & Diagnostics
Nov 2021

Mergers & Acquisitions
Healthcare Services
Nov 2021

Mergers & Acquisitions
HealthTech
Nov 2021

Initial Public Offering
Healthcare Services
Nov 2021

Initial Public Offering
Medtech
Oct 2021

Confidentially Marketed Follow-on Offering
Biopharma
Oct 2021

Confidentially Marketed Follow-on Offering
Medtech
Oct 2021

Mergers & Acquisitions
Medtech
Oct 2021

Follow-on Offering
Medtech
Oct 2021

Follow-on Offering
Healthcare & Special Situations
Oct 2021

Mergers & Acquisitions
Medtech
Oct 2021

Follow-on Offering
Healthcare Services
Sep 2021

Mergers & Acquisitions
Medtech
Sep 2021

Follow-on Offering
Biopharma
Sep 2021

SPAC Merger
Tools & Diagnostics
Sep 2021

Mergers & Acquisitions
Biopharma
Jul 2021

SPAC Merger & PIPE
Biopharma
Aug 2021

Initial Public Offering
Biopharma
Jul 2021

Initial Public Offering
Tools & Diagnostics
Jul 2021

Initial Public Offering
Biopharma
Jul 2021

Follow-on Offering
Entertainment
Jun 2021

Initial Public Offering (U.S. Nasdaq)
Medtech
Jul 2021

Confidentially Marketed Follow-on Offering
Medtech
Jul 2021

Confidentially Marketed Follow-on Offering
Biopharma
Jul 2021

Mergers & Acquisitions
Biopharma
Aug 2021

Initial Public Offering
Biopharma
Aug 2021

Initial Public Offering
HealthTech
Jul 2021

Mergers & Acquisitions
Biopharma
Jul 2021

Follow-on Offering
Biopharma
Jul 2021

Initial Public Offering
Biopharma
Jun 2021

Initial Public Offering
Tools & Diagnostics
Jul 2021

Initial Public Offering
Biopharma
Jun 2021

Mergers & Acquisitions
Healthcare Services
Jun 2021

SPAC Merger & PIPE
Biopharma
Feb 2021

PIPE
Biopharma
Mar 2021

PIPE
Biopharma
Feb 2021

Senior Notes
Healthcare Services
Feb 2021

Follow-on Offering
Medtech
Apr 2021

Has Invested in
Medtech
Mar 2021

Convertible Notes
Medtech
Mar 2021

Confidentially Marketed Follow-on Offering
Medtech
Feb 2021

Follow-on Offering
Biopharma
Apr 2021

Follow-on Offering
Biopharma
Mar 2021

Confidentially Marketed Follow-on Offering
Biopharma
Apr 2021

Confidentially Marketed Follow-on Offering
Medtech
Apr 2021

Follow-on Offering
Tools & Diagnostics
Apr 2021

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2021

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2021

Convertible Senior Notes
Biopharma
Apr 2021

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2021

Follow-on Offering
Biopharma
Mar 2021

Confidentially Marketed Follow-on Offering
Biopharma
Mar 2021

Initial Public Offering
Biopharma
Mar 2021

Confidentially Marketed Follow-on Offering
HealthTech
Mar 2021

Follow-on Offering
HealthTech
Feb 2021

Follow-on Offering
HealthTech
Feb 2021

Follow-on Offering
HealthTech
Feb 2021

Initial Public Offering
Biopharma
Feb 2021

Initial Public Offering
Biopharma
Feb 2021

Initial Public Offering
Biopharma
Feb 2021

Initial Public Offering
Biopharma
Dec 2020

Follow-on Offering
Biopharma
Jan 2021

Confidentially Marketed Follow-on Offering
Biopharma
Jan 2021

Private Placement
HealthTech
Feb 2021

Confidentially Marketed Follow-on Offering
Biopharma
Feb 2021

Initial Public Offering
Biopharma
Dec 2020

Follow-on Offering
Healthcare Services
Jan 2021

Follow-on Offering
Biopharma
Jan 2021

Follow-on Offering
Biopharma
Dec 2020

Follow-on Offering
Biopharma
Dec 2020

Follow-on Offering
Tools & Diagnostics
Dec 2020

Follow-on Offering
Tools & Diagnostics
Dec 2020

Initial Public Offering
Biopharma
Nov 2020

Initial Public Offering
Tools & Diagnostics
Dec 2020

Initial Public Offering
Medtech
Oct 2020

Mergers & Acquisitions
Biopharma
Oct 2020

Initial Public Offering
Medtech
Oct 2020

Initial Public Offering
Tools & Diagnostics
Nov 2020

Initial Public Offering
Biopharma
Sep 2020

Initial Public Offering
Biopharma
Sep 2020

Initial Public Offering
Medtech
Oct 2020

Confidentially Marketed Follow-on Offering
Biopharma
Jul 2020

Follow-on Offering
Biopharma
Aug 2020

Mergers & Acquisitions
Biopharma
Aug 2020

Convertible Notes
Biopharma
Sep 2020

PIPE
Biopharma
Jul 2020

Initial Public Offering
Biopharma
Jul 2020

PIPE
Biopharma
Jul 2020

Mergers & Acquisitions
Biopharma
Jul 2020
Currency volume represents full credit to each underwriter. All transaction announcements appear as a matter of record only. Stifel collectively refers to Stifel, Nicolaus & Company, Incorporated and other affiliated broker-dealer subsidiaries of Stifel Financial Corp.